FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808165240> ?p ?o ?g. }

• W2808165240 abstract "Metastatic triple-negative breast cancer (TNBC) is a heterogeneous and incurable disease. Numerous studies have been conducted to seek molecular targets to treat TNBC effectively, but chemotherapy is still the main choice for patients with TNBC. We have previously presented evidence of the important roles of interleukin-6 (IL-6) and chemokine (C-C motif) ligand 5 (CCL5) in TNBC tumor growth and metastasis. These experiments highlighted the importance of the crosstalk between cancer cells and stromal lymphatic endothelial cells (LECs) in tumor growth and metastasis. We examined the viability and migration of MDA-MB-231-LN, SUM149, and SUM159 cells co-cultured with LECs when treated with maraviroc (CCR5 inhibitor) and tocilizumab (anti-IL-6 receptor antibody). To assess the anti-tumor effects of the combination of these two drugs in an athymic nude mouse model, MDA-MB-231-LN cells were implanted in the mammary fat pad and maraviroc (8 mg/kg, orally daily) and cMR16-1 (murine surrogate of the anti-IL-6R antibody, 10 mg/kg, IP, 3 days a week) were administrated for 5 weeks and effects on tumor growth and thoracic metastasis were measured. In this study, we used maraviroc and tocilizumab to confirm that IL-6 and CCL5 signaling are key pathways promoting TNBC cell proliferation and migration. Further, in a xenograft mouse model, we showed that tumor growth was dramatically inhibited by cMR16-1, the mouse version of the anti-IL6R antibody. The combination of maraviroc and cMR16-1 caused significant reduction of TNBC tumor growth compared to the single agents. Significantly, the combination of maraviroc and cMR16-1 abrogated thoracic metastasis. Taken together, these findings show that IL-6 and CCL5 signaling, which promote crosstalk between TNBC and lymphatic vessels, are key enhancers of TNBC tumor growth and metastasis. Furthermore, these results demonstrate that a drug combination inhibiting these pathways may be a promising therapy for TNBC patients." @default.
• W2808165240 created "2018-06-21" @default.
• W2808165240 creator A5051726038 @default.
• W2808165240 creator A5069901102 @default.
• W2808165240 creator A5084973622 @default.
• W2808165240 date "2018-06-14" @default.
• W2808165240 modified "2023-10-18" @default.
• W2808165240 title "Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis" @default.
• W2808165240 cites W1798962454 @default.
• W2808165240 cites W1981631298 @default.
• W2808165240 cites W1986873446 @default.
• W2808165240 cites W2001868807 @default.
• W2808165240 cites W2006642493 @default.
• W2808165240 cites W2007640949 @default.
• W2808165240 cites W2014521014 @default.
• W2808165240 cites W2024411037 @default.
• W2808165240 cites W2030201335 @default.
• W2808165240 cites W2031563062 @default.
• W2808165240 cites W2039554844 @default.
• W2808165240 cites W2049184800 @default.
• W2808165240 cites W2049993590 @default.
• W2808165240 cites W2050104758 @default.
• W2808165240 cites W2064372507 @default.
• W2808165240 cites W2067526965 @default.
• W2808165240 cites W2077945404 @default.
• W2808165240 cites W2091004743 @default.
• W2808165240 cites W2093343694 @default.
• W2808165240 cites W2096439168 @default.
• W2808165240 cites W2102011984 @default.
• W2808165240 cites W2107554353 @default.
• W2808165240 cites W2116455112 @default.
• W2808165240 cites W2118282739 @default.
• W2808165240 cites W2135790901 @default.
• W2808165240 cites W2140154973 @default.
• W2808165240 cites W2145456893 @default.
• W2808165240 cites W2148883897 @default.
• W2808165240 cites W2162949913 @default.
• W2808165240 cites W2171543828 @default.
• W2808165240 cites W2187775989 @default.
• W2808165240 cites W2206057428 @default.
• W2808165240 cites W2215233832 @default.
• W2808165240 cites W2428008058 @default.
• W2808165240 cites W2586693937 @default.
• W2808165240 doi "https://doi.org/10.1186/s13058-018-0981-3" @default.
• W2808165240 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6000947" @default.
• W2808165240 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29898755" @default.
• W2808165240 hasPublicationYear "2018" @default.
• W2808165240 type Work @default.
• W2808165240 sameAs 2808165240 @default.
• W2808165240 citedByCount "56" @default.
• W2808165240 countsByYear W28081652402019 @default.
• W2808165240 countsByYear W28081652402020 @default.
• W2808165240 countsByYear W28081652402021 @default.
• W2808165240 countsByYear W28081652402022 @default.
• W2808165240 countsByYear W28081652402023 @default.
• W2808165240 crossrefType "journal-article" @default.
• W2808165240 hasAuthorship W2808165240A5051726038 @default.
• W2808165240 hasAuthorship W2808165240A5069901102 @default.
• W2808165240 hasAuthorship W2808165240A5084973622 @default.
• W2808165240 hasBestOaLocation W28081652401 @default.
• W2808165240 hasConcept C116484652 @default.
• W2808165240 hasConcept C121608353 @default.
• W2808165240 hasConcept C126322002 @default.
• W2808165240 hasConcept C12823836 @default.
• W2808165240 hasConcept C13373296 @default.
• W2808165240 hasConcept C143998085 @default.
• W2808165240 hasConcept C16930146 @default.
• W2808165240 hasConcept C170493617 @default.
• W2808165240 hasConcept C203014093 @default.
• W2808165240 hasConcept C2776090121 @default.
• W2808165240 hasConcept C2778899366 @default.
• W2808165240 hasConcept C2779013556 @default.
• W2808165240 hasConcept C2780110267 @default.
• W2808165240 hasConcept C2780140570 @default.
• W2808165240 hasConcept C3013748606 @default.
• W2808165240 hasConcept C37044404 @default.
• W2808165240 hasConcept C502942594 @default.
• W2808165240 hasConcept C530470458 @default.
• W2808165240 hasConcept C71924100 @default.
• W2808165240 hasConcept C79484868 @default.
• W2808165240 hasConcept C8891405 @default.
• W2808165240 hasConceptScore W2808165240C116484652 @default.
• W2808165240 hasConceptScore W2808165240C121608353 @default.
• W2808165240 hasConceptScore W2808165240C126322002 @default.
• W2808165240 hasConceptScore W2808165240C12823836 @default.
• W2808165240 hasConceptScore W2808165240C13373296 @default.
• W2808165240 hasConceptScore W2808165240C143998085 @default.
• W2808165240 hasConceptScore W2808165240C16930146 @default.
• W2808165240 hasConceptScore W2808165240C170493617 @default.
• W2808165240 hasConceptScore W2808165240C203014093 @default.
• W2808165240 hasConceptScore W2808165240C2776090121 @default.
• W2808165240 hasConceptScore W2808165240C2778899366 @default.
• W2808165240 hasConceptScore W2808165240C2779013556 @default.
• W2808165240 hasConceptScore W2808165240C2780110267 @default.
• W2808165240 hasConceptScore W2808165240C2780140570 @default.
• W2808165240 hasConceptScore W2808165240C3013748606 @default.
• W2808165240 hasConceptScore W2808165240C37044404 @default.
• W2808165240 hasConceptScore W2808165240C502942594 @default.
• W2808165240 hasConceptScore W2808165240C530470458 @default.
• W2808165240 hasConceptScore W2808165240C71924100 @default.

• next